Shakeela Bahadur, MD

Articles by Shakeela Bahadur, MD

Dr Bahadur on the Shift in Frontline CDK4/6 Inhibitor Selection in HR+/ HER2– Breast Cancer Breast Cancer

July 6th 2023

Shakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.

Latest Updated Articles

Trending on OncLive

FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC

Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer

Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer

CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition

NDA Submission Completed for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion–Positive NSCLC